{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:28:40Z","timestamp":1791646120626,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Postgraduate Research & Practice Innovation Program of Harbin Medical University","award":["YJSCX2023-32HYD"],"award-info":[{"award-number":["YJSCX2023-32HYD"]}]},{"name":"Scientific Research Project of Heilongjiang Provincial Health Commission","award":["20240202010154"],"award-info":[{"award-number":["20240202010154"]}]},{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","award":["LH2022H099"],"award-info":[{"award-number":["LH2022H099"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91278-4","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T03:02:51Z","timestamp":1740711771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Dapagliflozin inhibits ferroptosis and ameliorates renal fibrosis in diabetic C57BL\/6J mice"],"prefix":"10.1038","volume":"15","author":[{"given":"Zhen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranyu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"91278_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41581-020-0278-5","volume":"16","author":"JB Cole","year":"2020","unstructured":"Cole, J. B. & Florez, J. C. Genetics of diabetes mellitus and diabetes complications. Nat. Rev. Nephrol. 16, 377\u2013390. https:\/\/doi.org\/10.1038\/s41581-020-0278-5 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"91278_CR2","doi-asserted-by":"publisher","first-page":"1173933","DOI":"10.3389\/fendo.2023.1173933","volume":"14","author":"K Zhang","year":"2023","unstructured":"Zhang, K. et al. The role of cellular crosstalk in the progression of diabetic nephropathy. Front. Endocrinol. (Lausanne). 14, 1173933. https:\/\/doi.org\/10.3389\/fendo.2023.1173933 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"91278_CR3","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.tem.2016.07.002","volume":"27","author":"L Gnudi","year":"2016","unstructured":"Gnudi, L., Coward, R. J. M. & Long, D. A. Diabetic nephropathy: Perspective on novel molecular mechanisms. Trends Endocrinol. Metab. 27, 820\u2013830. https:\/\/doi.org\/10.1016\/j.tem.2016.07.002 (2016).","journal-title":"Trends Endocrinol. Metab."},{"key":"91278_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrneph.2014.116","volume":"10","author":"M Kato","year":"2014","unstructured":"Kato, M. & Natarajan, R. Diabetic nephropathy\u2013emerging epigenetic mechanisms. Nat. Rev. Nephrol. 10, 517\u2013530. https:\/\/doi.org\/10.1038\/nrneph.2014.116 (2014).","journal-title":"Nat. Rev. Nephrol."},{"key":"91278_CR5","doi-asserted-by":"publisher","unstructured":"Hung, P. H., Hsu, Y. C., Chen, T. H. & Lin, C. L. Recent advances in diabetic kidney diseases: from kidney injury to kidney fibrosis. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms222111857 (2021).","DOI":"10.3390\/ijms222111857"},{"key":"91278_CR6","doi-asserted-by":"publisher","first-page":"860588","DOI":"10.3389\/fphar.2022.860588","volume":"13","author":"XY Yu","year":"2022","unstructured":"Yu, X. Y., Sun, Q., Zhang, Y. M., Zou, L. & Zhao, Y. Y. TGF-\u03b2\/Smad signaling pathway in tubulointerstitial fibrosis. Front. Pharmacol. 13, 860588. https:\/\/doi.org\/10.3389\/fphar.2022.860588 (2022).","journal-title":"Front. Pharmacol."},{"key":"91278_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-\u03b2: The master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325\u2013338. https:\/\/doi.org\/10.1038\/nrneph.2016.48 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"91278_CR8","doi-asserted-by":"publisher","unstructured":"Park, C. H. & Yoo, T. H. TGF-\u03b2 inhibitors for therapeutic management of kidney fibrosis. Pharmaceuticals (Basel). 15. https:\/\/doi.org\/10.3390\/ph15121485 (2022).","DOI":"10.3390\/ph15121485"},{"key":"91278_CR9","doi-asserted-by":"publisher","first-page":"7642","DOI":"10.1111\/jcmm.16601","volume":"25","author":"J Tian","year":"2021","unstructured":"Tian, J. et al. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats. J. Cell. Mol. Med. 25, 7642\u20137659. https:\/\/doi.org\/10.1111\/jcmm.16601 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"91278_CR10","doi-asserted-by":"publisher","first-page":"108687","DOI":"10.1016\/j.jdiacomp.2024.108687","volume":"38","author":"M Jiang","year":"2024","unstructured":"Jiang, M., Yang, Z., Lyu, L. & Shi, M. Dapagliflozin attenuates renal fibrosis by suppressing angiotensin II\/TGF\u03b2 signaling in diabetic mice. J. Diabetes Complications. 38, 108687. https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108687 (2024).","journal-title":"J. Diabetes Complications"},{"key":"91278_CR11","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/cm9.0000000000002784","volume":"137","author":"X Qiu","year":"2024","unstructured":"Qiu, X., Bi, Q., Wu, J., Sun, Z. & Wang, W. Role of ferroptosis in fibrosis: From mechanism to potential therapy. Chin. Med. J. (Engl). 137, 806\u2013817. https:\/\/doi.org\/10.1097\/cm9.0000000000002784 (2024).","journal-title":"Chin. Med. J. (Engl)"},{"key":"91278_CR12","doi-asserted-by":"publisher","first-page":"103466","DOI":"10.1016\/j.autrev.2023.103466","volume":"23","author":"D Roccatello","year":"2024","unstructured":"Roccatello, D. et al. From inflammation to renal fibrosis: A one-way road in autoimmunity? Autoimmun. Rev. 23, 103466. https:\/\/doi.org\/10.1016\/j.autrev.2023.103466 (2024).","journal-title":"Autoimmun. Rev."},{"key":"91278_CR13","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042 (2012).","journal-title":"Cell"},{"key":"91278_CR14","doi-asserted-by":"publisher","first-page":"1294317","DOI":"10.3389\/fimmu.2023.1294317","volume":"14","author":"J Li","year":"2023","unstructured":"Li, J. et al. Ferroptosis: An important player in the inflammatory response in diabetic nephropathy. Front. Immunol. 14, 1294317. https:\/\/doi.org\/10.3389\/fimmu.2023.1294317 (2023).","journal-title":"Front. Immunol."},{"key":"91278_CR15","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.ekir.2024.04.012","volume":"9","author":"J Chu","year":"2024","unstructured":"Chu, J. et al. Advances of Iron and ferroptosis in diabetic kidney disease. Kidney Int. Rep. 9, 1972\u20131985. https:\/\/doi.org\/10.1016\/j.ekir.2024.04.012 (2024).","journal-title":"Kidney Int. Rep."},{"key":"91278_CR16","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N Engl. J. Med. 383, 1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816 (2020).","journal-title":"N Engl. J. Med."},{"key":"91278_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-021-04211-w","volume":"601","author":"L Han","year":"2022","unstructured":"Han, L. et al. Structure and mechanism of the SGLT family of glucose transporters. Nature 601, 274\u2013279. https:\/\/doi.org\/10.1038\/s41586-021-04211-w (2022).","journal-title":"Nature"},{"key":"91278_CR18","doi-asserted-by":"publisher","unstructured":"Huang, Y., Lu, W. & Lu, H. The clinical efficacy and safety of Dapagliflozin in patients with diabetic nephropathy. Diabetol. Metab. Syndr. 14. https:\/\/doi.org\/10.1186\/s13098-022-00815-y (2022).","DOI":"10.1186\/s13098-022-00815-y"},{"key":"91278_CR19","doi-asserted-by":"publisher","unstructured":"DeFronzo, R. A. SGLT2 inhibitors: cardiorenal metabolic drugs for the ages. J. Clin. Invest. 134. https:\/\/doi.org\/10.1172\/jci177625 (2024).","DOI":"10.1172\/jci177625"},{"key":"91278_CR20","doi-asserted-by":"publisher","first-page":"1205834","DOI":"10.3389\/fimmu.2023.1205834","volume":"14","author":"A Cai","year":"2023","unstructured":"Cai, A. et al. Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels. Front. Immunol. 14, 1205834. https:\/\/doi.org\/10.3389\/fimmu.2023.1205834 (2023).","journal-title":"Front. Immunol."},{"key":"91278_CR21","doi-asserted-by":"publisher","first-page":"1078205","DOI":"10.3389\/fphar.2023.1078205","volume":"14","author":"W Chen","year":"2023","unstructured":"Chen, W. et al. Dapagliflozin alleviates myocardial ischemia\/reperfusion injury by reducing ferroptosis via MAPK signaling Inhibition. Front. Pharmacol. 14, 1078205. https:\/\/doi.org\/10.3389\/fphar.2023.1078205 (2023).","journal-title":"Front. Pharmacol."},{"key":"91278_CR22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1089\/ars.2022.0169","volume":"40","author":"YH Wang","year":"2024","unstructured":"Wang, Y. H., Chang, D. Y., Zhao, M. H. & Chen, M. Dapagliflozin alleviates diabetic kidney disease via hypoxia inducible factor 1\u03b1\/Heme Oxygenase 1-Mediated ferroptosis. Antioxid. Redox Signal. 40, 492\u2013509. https:\/\/doi.org\/10.1089\/ars.2022.0169 (2024).","journal-title":"Antioxid. Redox Signal."},{"key":"91278_CR23","doi-asserted-by":"publisher","unstructured":"Huang, B., Wen, W. & Ye, S. Dapagliflozin ameliorates renal tubular ferroptosis in diabetes via SLC40A1 stabilization. Oxid. Med. Cell. Longev. 2022, 9735555. https:\/\/doi.org\/10.1155\/2022\/9735555 (2022).","DOI":"10.1155\/2022\/9735555"},{"key":"91278_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","volume":"43","author":"C Nogales","year":"2022","unstructured":"Nogales, C. et al. Network pharmacology: Curing causal mechanisms instead of treating symptoms. Trends Pharmacol. Sci. 43, 136\u2013150. https:\/\/doi.org\/10.1016\/j.tips.2021.11.004 (2022).","journal-title":"Trends Pharmacol. Sci."},{"key":"91278_CR25","doi-asserted-by":"publisher","first-page":"714440","DOI":"10.3389\/fcimb.2021.714440","volume":"11","author":"JE Sinclair","year":"2021","unstructured":"Sinclair, J. E. et al. Type I diabetes mellitus increases the cardiovascular complications of influenza virus infection. Front. Cell. Infect. Microbiol. 11, 714440. https:\/\/doi.org\/10.3389\/fcimb.2021.714440 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"91278_CR26","doi-asserted-by":"publisher","first-page":"115818","DOI":"10.1016\/j.biopha.2023.115818","volume":"168","author":"H Shu","year":"2023","unstructured":"Shu, H. et al. Circular RNAs: An emerging precise weapon for diabetic nephropathy diagnosis and therapy. Biomed. Pharmacother. 168, 115818. https:\/\/doi.org\/10.1016\/j.biopha.2023.115818 (2023).","journal-title":"Biomed. Pharmacother"},{"key":"91278_CR27","doi-asserted-by":"publisher","unstructured":"Khalid, M., Petroianu, G. & Adem, A. Advanced glycation end products and diabetes mellitus: Mechanisms and perspectives. Biomolecules 12, (2022). https:\/\/doi.org\/10.3390\/biom12040542","DOI":"10.3390\/biom12040542"},{"key":"91278_CR28","doi-asserted-by":"publisher","first-page":"1236686","DOI":"10.3389\/fendo.2023.1236686","volume":"14","author":"P Paul","year":"2023","unstructured":"Paul, P. et al. Nanomedicines for the management of diabetic nephropathy: present progress and prospects. Front. Endocrinol. (Lausanne). 14, 1236686. https:\/\/doi.org\/10.3389\/fendo.2023.1236686 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"91278_CR29","doi-asserted-by":"publisher","first-page":"e23529","DOI":"10.1002\/dvg.23529","volume":"62","author":"S Hadpech","year":"2024","unstructured":"Hadpech, S. & Thongboonkerd, V. Epithelial-mesenchymal plasticity in kidney fibrosis. Genesis 62, e23529. https:\/\/doi.org\/10.1002\/dvg.23529 (2024).","journal-title":"Genesis"},{"key":"91278_CR30","doi-asserted-by":"publisher","first-page":"945976","DOI":"10.3389\/fendo.2022.945976","volume":"13","author":"Y Wu","year":"2022","unstructured":"Wu, Y. & Chen, Y. Research progress on ferroptosis in diabetic kidney disease. Front. Endocrinol. (Lausanne). 13, 945976. https:\/\/doi.org\/10.3389\/fendo.2022.945976 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"91278_CR31","doi-asserted-by":"publisher","unstructured":"Li, S. et al. Role of ferroptosis in chronic kidney disease. Cell. Commun. Signal. 22 https:\/\/doi.org\/10.1186\/s12964-023-01422-8 (2024).","DOI":"10.1186\/s12964-023-01422-8"},{"key":"91278_CR32","doi-asserted-by":"publisher","first-page":"654557","DOI":"10.3389\/fmed.2021.654557","volume":"8","author":"M Provenzano","year":"2021","unstructured":"Provenzano, M. et al. Sodium-glucose co-transporter-2 inhibitors and nephroprotection in diabetic patients: More than a challenge. Front. Med. (Lausanne). 8, 654557. https:\/\/doi.org\/10.3389\/fmed.2021.654557 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"91278_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/dom.13923","volume":"22","author":"RA Scholtes","year":"2020","unstructured":"Scholtes, R. A. et al. The effects of Dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: A post hoc analysis. Diabetes Obes. Metab. 22, 549\u2013556. https:\/\/doi.org\/10.1111\/dom.13923 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"91278_CR34","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1080\/03007995.2017.1354822","volume":"33","author":"S Jabbour","year":"2017","unstructured":"Jabbour, S. Durability of response to Dapagliflozin: A review of long-term efficacy and safety. Curr. Med. Res. Opin. 33, 1685\u20131696. https:\/\/doi.org\/10.1080\/03007995.2017.1354822 (2017).","journal-title":"Curr. Med. Res. Opin."},{"key":"91278_CR35","doi-asserted-by":"publisher","first-page":"e58115","DOI":"10.7759\/cureus.58115","volume":"16","author":"M Dharmalingam","year":"2024","unstructured":"Dharmalingam, M. et al. Evaluating the efficacy, safety, and tolerability of combination therapy of Dapagliflozin and linagliptin over Dapagliflozin and vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with Metformin. Cureus 16, e58115. https:\/\/doi.org\/10.7759\/cureus.58115 (2024).","journal-title":"Cureus"},{"key":"91278_CR36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fendo.2019.00441","volume":"10","author":"F Huang","year":"2019","unstructured":"Huang, F. et al. Dapagliflozin attenuates renal tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1\/TGF\u03b21 signaling. Front. Endocrinol. (Lausanne). 10, 441. https:\/\/doi.org\/10.3389\/fendo.2019.00441 (2019).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"91278_CR37","doi-asserted-by":"publisher","first-page":"1095487","DOI":"10.3389\/fphar.2023.1095487","volume":"14","author":"J Zeng","year":"2023","unstructured":"Zeng, J. et al. Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-\u03b21\/MAPK mediated mitochondrial damage. Front. Pharmacol. 14, 1095487. https:\/\/doi.org\/10.3389\/fphar.2023.1095487 (2023).","journal-title":"Front. Pharmacol."},{"key":"91278_CR38","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3892\/etm.2023.12271","volume":"26","author":"S Xue","year":"2023","unstructured":"Xue, S., Li, Y. X., Lu, X. X. & Tang, W. Dapagliflozin can alleviate renal fibrosis in rats with streptozotocin\u2013induced type 2 diabetes mellitus. Exp. Ther. Med. 26, 572. https:\/\/doi.org\/10.3892\/etm.2023.12271 (2023).","journal-title":"Exp. Ther. Med."},{"key":"91278_CR39","doi-asserted-by":"publisher","first-page":"873108","DOI":"10.3389\/fphar.2022.873108","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. Dapagliflozin attenuates myocardial fibrosis by inhibiting the TGF-\u03b21\/Smad signaling pathway in a normoglycemic rabbit model of chronic heart failure. Front. Pharmacol. 13, 873108. https:\/\/doi.org\/10.3389\/fphar.2022.873108 (2022).","journal-title":"Front. Pharmacol."},{"key":"91278_CR40","doi-asserted-by":"publisher","first-page":"149972","DOI":"10.1016\/j.bbrc.2024.149972","volume":"721","author":"X Zeng","year":"2024","unstructured":"Zeng, X. et al. Mitigation of ROS-triggered endoplasmic reticulum stress by upregulating Nrf2 retards diabetic nephropathy. Biochem. Biophys. Res. Commun. 721, 149972. https:\/\/doi.org\/10.1016\/j.bbrc.2024.149972 (2024).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"91278_CR41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.freeradbiomed.2020.10.323","volume":"162","author":"S Li","year":"2021","unstructured":"Li, S., Zheng, L., Zhang, J., Liu, X. & Wu, Z. Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathy. Free Radic Biol. Med. 162, 435\u2013449. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.10.323 (2021).","journal-title":"Free Radic Biol. Med."},{"key":"91278_CR42","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","volume":"18","author":"D Tang","year":"2023","unstructured":"Tang, D. et al. SRplot: A free online platform for data visualization and graphing. PLoS One. 18, e0294236. https:\/\/doi.org\/10.1371\/journal.pone.0294236 (2023).","journal-title":"PLoS One"},{"key":"91278_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-1-0716-3441-7_6","volume":"2714","author":"Y Liu","year":"2024","unstructured":"Liu, Y. & Cao, Y. Protein-ligand blind docking using CB-Dock2. Methods Mol. Biol. 2714, 113\u2013125. https:\/\/doi.org\/10.1007\/978-1-0716-3441-7_6 (2024).","journal-title":"Methods Mol. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91278-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T03:03:01Z","timestamp":1740711781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91278-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91278"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91278-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"17 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7117"}}